BRIEF published on 10/02/2026 at 00:40, 1 hour 59 minutes ago Medicure octroie des options d'achat d'actions à son personnel clé Options D'achat D'actions Medicure Inc. Marché Américain Médicaments Approbation De La TSX
BRIEF published on 10/02/2026 at 00:40, 1 hour 59 minutes ago Medicure Grants Stock Options to Key Personnel Stock Options Pharmaceuticals Medicure Inc. U.S. Market TSX Approval
PRESS RELEASE published on 10/02/2026 at 00:35, 2 hours 4 minutes ago Medicure Announces Grant of Stock Options Medicure Inc. grants stock options to directors, officers, employees, and consultants, aiming at the development and commercialization of pharmaceuticals in the US market Stock Options Pharmaceuticals Medicure Inc. US Market Healthcare Products
BRIEF published on 09/29/2026 at 00:05, 3 days 2 hours ago Medicure termine le recrutement pour l'essai clinique de phase 3 MEND-PNPO Essai Clinique Approbation De La FDA MC-1 Médecine Déficit En PNPO
BRIEF published on 09/29/2026 at 00:05, 3 days 2 hours ago Medicure Completes Enrollment in MEND-PNPO Phase 3 Clinical Trial FDA Approval Clinical Trial Medicure MC-1 PNPO Deficiency
PRESS RELEASE published on 09/29/2026 at 00:00, 3 days 2 hours ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial Medicure completes patient enrollment in MEND-PNPO Phase 3 study evaluating MC-1 for PNPO deficiency. Study progress discussed, including FDA designations and future conference presentations Medicure MC-1 PNPO Deficiency MEND-PNPO FDA Designations
BRIEF published on 09/09/2026 at 00:30, 23 days 2 hours ago Medicure dévoile les données de son étude de phase 3 au Congrès européen de l'épilepsie Medicure Inc. Étude MEND-PNPO Déficit En PNPO Essai MC-1 Congrès Sur L'épilepsie
BRIEF published on 09/09/2026 at 00:30, 23 days 2 hours ago Medicure Unveils Phase 3 Study Data at European Epilepsy Congress Medicure Inc. PNPO Deficiency MEND-PNPO Study MC-1 Trial Epilepsy Congress
PRESS RELEASE published on 09/09/2026 at 00:25, 23 days 2 hours ago Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress Medicure Inc. presents design and data from MEND-PNPO Phase 3 study on PNPO deficiency treatment at European Epilepsy Congress. Not FDA-approved yet Clinical Trials Drug Development Medicure Inc. PNPO Deficiency MEND-PNPO
BRIEF published on 08/14/2026 at 23:05, 1 month 18 days ago Medicure annonce ses résultats financiers du deuxième trimestre 2026 et la tenue d'une prochaine conférence téléphonique. Résultats Financiers Medicure Inc. Augmentation Des Revenus ZYPITAMAG® Segment Pharmaceutique
Published on 10/01/2026 at 23:05, 3 hours 34 minutes ago Vox Royalty Expands Revolving Credit Facility Up to $150 Million and Strengthens Leadership Team
Published on 10/01/2026 at 22:00, 4 hours 39 minutes ago Golden Minerals Company Announces New Management Appointments and Resignation of Mr. Pablo Castanos
Published on 10/01/2026 at 19:05, 7 hours 34 minutes ago PEL 90 Participating Interest Exchange with Chevron
Published on 10/02/2026 at 00:01, 2 hours 38 minutes ago PolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
Published on 10/01/2026 at 23:15, 3 hours 24 minutes ago CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies
Published on 10/01/2026 at 20:45, 5 hours 54 minutes ago Ditto Named a Product Leader in KuppingerCole Analysts Leadership Compass for Identity Verification
Published on 10/01/2026 at 20:30, 6 hours 9 minutes ago Eleving Group prices EUR 200 million senior secured bonds at 9% in private placement – EUR 25 million exchange offer to follow
Published on 10/01/2026 at 18:55, 7 hours 44 minutes ago Ondo Finance Announces Expansion of Ondo Intelligent Portfolios to Seven With New Magnificent 7, AI and Targeted Portfolios
Published on 10/01/2026 at 19:00, 7 hours 39 minutes ago AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 19:00, 7 hours 39 minutes ago AMA CORP PLC réduit sa structure de coûts tout en préservant les fonctions clés de XpertEye
Published on 10/01/2026 at 18:40, 7 hours 58 minutes ago Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:40, 7 hours 58 minutes ago TF1 - Déclaration mensuelle des actions et droits de vote - Septembre 2026
Published on 10/01/2026 at 18:07, 8 hours 32 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
